CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 12 clinical trials at NIH that match your search criteria

Cancer by treatment type: Vaccine

Trial and Protocol Number Brain Tumor	Principal Investigator	Referral Contact
A Phase I Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM) NCI-11-C-0192, NCT01386463	Joohee Sul 301-594-9349	Tracy Cropper 301-402-6298 Toll free: 866-251-9686 tcropper@mail.nih.gov

Trial and Protocol Number Hematologic/Blood Cancers	Principal Investigator	Referral Contact
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies NCI-08-C-0051, NCT00923910	Alan S. Wayne 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)

Trial and Protocol Number Lung Cancer	Principal Investigator	Referral Contact
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum NCI-12-C-0151, NCT01624090	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum NCI-11-C-0111, NCT01313429	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas NCI-10-C-0138, NCT01143545	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov

Trial and Protocol Number Malignant Mesothelioma	Principal Investigator	Referral Contact
A Phase IB Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma NCI-12-C-0170, NCT01675765	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov

Trial and Protocol Number Prostate Cancer	Principal Investigator	Referral Contact
A Randomized, Double-Blind, Phase III Efficacy Trial of PROSTVAC-V/F Plus or Minus GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer NCI-11-C-0262, NCT01322490	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Randomized Phase II Study of L-BLP25 in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Newly Diagnosed, High Risk Prostate Cancer Patients NCI-11-C-0247	Ravi A. Madan 301-496-3493	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer NCI-07-C-0107, NCT00450463	Ravi A. Madan 301-496-3493	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression NCI-13-C-0016, NCT01730118	Lauren V. Wood 301-402-0199	Brenda Roberson 301-435-4733 broberson@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors NCI-12-C-0056, NCT01519817	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy NCI-11-C-0146, NCT01339000	Claude Sportès 301-435-5280	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.